# US Nucleic Acid Therapeutics Market

> United States Nucleic Acid Therapeutics Market Research Report: Size, Share, Trend Analysis By Products (Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers, RNA interference [RNAi] and short interfering RNAs [siRNAs], and Others), By Applications (Monogenetic Disorders and Multi-genetic Disorders), By End Users (Hospitals and Clinics and Academic and Research Institutes) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 3.74%
- **2024:** $ 131.19 Million
- **2025:** $ 136.6 Million
- **2035:** $ 196.45 Million
- **Key Players:** Amgen Inc (US), Gilead Sciences Inc (US), Regeneron Pharmaceuticals Inc (US), Vertex Pharmaceuticals Inc (US), Ionis Pharmaceuticals Inc (US), Sarepta Therapeutics Inc (US), Alnylam Pharmaceuticals Inc (US), Novartis AG (US)

**Report ID:** MRFR/HC/11123-HCR · **Pages:** 128 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-nucleic-acid-therapeutics-market-12646

---

## Market Summary

## **United States Nucleic Acid Therapeutics Market Overview**

The nucleic acid therapeutics market industry is projected to grow from USD Significant by 2032, exhibiting a compound annual growth rate (CAGR) of 10.10% during the forecast period (2023 - 2032). The development of biological products, DNA therapies, and the growth of the pharmaceutical and healthcare industries are all significant market drivers that have propelled the nucleic acid therapeutics market upward.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

## **United States Nucleic Acid Therapeutics Market Trends**

The demand for nucleic acid-based therapeutics—which correct aberrant gene expression to treat diseases like cancer, sickle cell anemia, cystic fibrosis, Duchenne muscular dystrophy, thalassemia, and others—is primarily driven by the rising prevalence of genetic diseases. For instance, data from the Cystic Fibrosis Foundation released in July 2022 states that 40,000 adults and children in the US have cystic fibrosis (CF). Thus, the market is anticipated to benefit from the high prevalence of cystic fibrosis in the US population.

Furthermore, novel therapeutic pharmaceuticals are becoming more readily available in the market as a result of companies' increasing focus on partnerships, collaborations, new product launches, and other initiatives. This might potentially drive the market's expansion. For example, in an effort to improve the treatment efficacy of antisense oligonucleotides in Charcot-Marie-Tooth disease, the CMT Research Foundation and Nanite Inc. joined in February 2023.

Governments, drug manufacturers, and biotechnology businesses are investing more money in nucleic acid-based therapies research and development. This monetary assistance has stimulated creativity and expedited the introduction of novel treatments to the market. Additionally, regulatory bodies like the Food and Drug Administration (FDA) in the United States have streamlined the clearance process for nucleic acid-based medicines and created clear criteria. The expansion of the market has been fueled by these regulatory frameworks, which have incentivized companies to spend in the development of these therapies.

Moreover, in the market for nucleic acid therapeutics, cooperation between pharmaceutical corporations, biotechnology businesses, and academic institutions has increased. Partnerships speed up the creation and marketing of new products by facilitating the sharing of information, the pooling of resources, and technological improvements. Thus, driving the nucleic acid therapeutics market revenue.

## **United States Nucleic Acid Therapeutics Market Segment Insights**

### **US Nucleic Acid Therapeutics Product Insights**

The US Nucleic Acid Therapeutics market segmentation, based on product includes Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers, RNA interference [RNAi] and short interfering RNAs [siRNAs], and Others. The anti-sense oligonucleotides (ASOs) segment dominated the market mostly. Antisense oligonucleotides (ASOs) are single-stranded, short RNA or DNA molecules that can attach themselves to particular messenger RNA (mRNA) sequences and cause the targeted mRNA to either degrade or not translate into a protein. This characteristic renders ASOs a potentially effective treatment approach for a range of ailments, encompassing genetic abnormalities, infectious diseases, and cancer.

### **US Nucleic Acid Therapeutics Application Insights**

The US Nucleic Acid Therapeutics market segmentation, based on application, includes Monogenetic Disorders and Multi-genetic Disorders. The monogenetic disorders category generated the most income because most disorders that are treated with nucleic acid therapies are genetic and quite common. The primary driver of the nucleic acid therapeutics market expansion is the introduction of recently developed and authorized treatments for single gene defects by leading industry players. The top players in the field are concentrating on creating novel approaches to address issues with stability, off-targets, and gene quality in multi-genetic illnesses.

**Figure 1: US Nucleic Acid Therapeutics Market, by Application, 2022 & 2032 (USD Billion)**

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

### **US Nucleic Acid Therapeutics End User Insights**

The US Nucleic Acid Therapeutics market segmentation, based on end user, includes Hospitals and Clinics and Academic and Research Institutes. The hospitals and clinics category generated the most income. As more treatments and immunizations are used to address a wide range of chronic illnesses, the market for customized pharmaceuticals is growing. This market sector is also being driven by the increasing number of people visiting hospitals and clinics.

### **US Nucleic Acid Therapeutics Regional Insights**

The US nucleic acid therapeutics market area will grow at a significant rate because new nucleic acid treatments are becoming more and more approved, and because nucleic acid extraction technology is readily available. The nation's market growth has reached its pinnacle and is anticipated to stay there for the duration of the projection period due to the availability of all positive elements. Additionally, the need for nucleic acid-based therapeutics is rising due to the increasing frequency of autoimmune illnesses in the population, which could boost the market's growth.

For example, in June 2022 the Autoimmune Association reported that over 31 million Americans suffer from autoimmune disorders, which are classified as 80–150 distinct chronic conditions. This demonstrates how common autoimmune diseases are in the intended audience.

**United States Nucleic Acid Therapeutics Key Market Players & Competitive Insights**

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the nucleic acid therapeutics market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, nucleic acid therapeutics industry must offer cost-effective items.

**Key Companies in the us nucleic acid therapeutics market include**

## **United States Nucleic Acid Therapeutics Market Segmentation**

### **US Nucleic Acid Therapeutics Products Outlook**

### **US Nucleic Acid Therapeutics Application Outlook**

### **US Nucleic Acid Therapeutics End User Outlook**

## Market Drivers

### Supportive Regulatory Environment

The supportive regulatory environment in the United States is a significant driver for the US [Nucleic Acid Based Therapeutics](https://www.marketresearchfuture.com/reports/nucleic-acid-based-therapeutics-market-2978) Market. The Food and Drug Administration (FDA) has established frameworks to expedite the approval of innovative therapies, including nucleic acid-based treatments. Initiatives such as the [Breakthrough Therapy Designation](https://www.marketresearchfuture.com/reports/breakthrough-therapy-designation-market-9063) and the Orphan Drug Act are designed to encourage the development of therapies for rare diseases. This regulatory support not only accelerates the time to market for new therapies but also provides financial incentives for developers. As a result, the market is likely to see an influx of new nucleic acid-based therapeutics, enhancing treatment options for patients.

### Increased Investment in Biotechnology

Investment in biotechnology is a key driver for the US Nucleic Acid Based Therapeutics Market. Venture capital funding and public-private partnerships are on the rise, with billions of dollars being allocated to research and development of nucleic acid therapies. In 2025, the biotechnology sector attracted over $50 billion in investments, reflecting a robust interest in innovative therapeutic approaches. This influx of capital is facilitating the development of novel therapies, including RNA-based treatments and gene therapies, which are gaining traction in clinical trials. As funding continues to flow into this sector, it is likely to accelerate the pace of innovation and commercialization of nucleic acid-based therapeutics.

### Growing Prevalence of Genetic Disorders

The US Nucleic Acid Based Therapeutics Market is experiencing growth due to the increasing prevalence of genetic disorders. Conditions such as cystic fibrosis, hemophilia, and muscular dystrophy are becoming more common, leading to a heightened demand for targeted therapies. According to the National Institutes of Health, approximately 1 in 10 Americans are affected by a genetic disorder, which underscores the urgent need for innovative treatments. This rising incidence is prompting pharmaceutical companies to invest in nucleic acid-based therapies, as they offer the potential for more effective and personalized treatment options. The market is projected to expand significantly as healthcare providers seek to address these complex conditions with advanced therapeutic solutions.

### Technological Advancements in Delivery Systems

Technological advancements in delivery systems are significantly influencing the US Nucleic Acid Based Therapeutics Market. Innovations such as lipid nanoparticles and viral vectors are enhancing the efficacy and safety of nucleic acid therapies. These delivery systems are crucial for ensuring that therapeutic agents reach their intended targets within the body. For instance, the successful use of lipid nanoparticles in mRNA vaccines has demonstrated the potential of these technologies in delivering nucleic acid-based therapies. As research continues to evolve, it is anticipated that more efficient and targeted delivery mechanisms will emerge, further propelling the growth of the market.

### Rising Awareness and Acceptance of Gene Therapies

Rising awareness and acceptance of gene therapies are contributing to the expansion of the US Nucleic Acid Based Therapeutics Market. As patients and healthcare providers become more informed about the benefits of gene therapies, there is a growing willingness to explore these options for treatment. Educational initiatives and advocacy groups are playing a pivotal role in disseminating information about the potential of nucleic acid-based therapies. This shift in perception is likely to lead to increased patient demand and, consequently, a larger market for these innovative treatments. The acceptance of gene therapies is expected to grow as more successful case studies emerge, showcasing their effectiveness in treating previously untreatable conditions.

## Future Outlook

The US Nucleic Acid Based Therapeutics Market is projected to grow at a 3.74% CAGR from 2025 to 2035, driven by advancements in gene editing, personalized medicine, and increasing R&D investments.

**New opportunities:**

- Development of targeted RNA therapies for rare diseases. Expansion of CRISPR technology applications in agriculture. Partnerships with biotech firms for innovative delivery systems.

By 2035, the market is expected to solidify its position as a leader in therapeutic innovation.

## Segment Insights

### By Application: Gene Therapy (Largest) vs. RNA Interference (Fastest-Growing)

In the US Nucleic Acid Based Therapeutics Market, Gene Therapy holds the largest market share among various applications. This category is primarily driven by advancements in genetic modification techniques and growing investments in gene therapy research. RNA Interference, although smaller in market share, is recognized as the fastest-growing segment due to increasing prevalence of chronic diseases and the need for innovative treatment options. The ongoing clinical trials and regulatory approvals are key factors enhancing the competitive landscape, driving adoption and acceptance in the medical community. The growth trends in this segment indicate a robust future for both Gene Therapy and RNA Interference. Factors such as rising healthcare expenditure, technological advancements, and an increasing patient population seeking advanced treatment options contribute to this growth. The focus on precision medicine and personalized therapies further bolsters the development of these applications, highlighting a significant shift towards targeted treatments. Pharmaceutical companies are actively exploring partnerships and collaboration, resulting in a vibrant ecosystem fostering innovation and bringing novel therapeutic solutions to the forefront.

Gene Therapy (Dominant) vs. RNA Interference (Emerging)

Gene Therapy represents the dominant application in the US Nucleic Acid Based Therapeutics Market, characterized by its ability to treat genetic disorders by delivering therapeutic genes directly into a patient's cells. This application embraces various methodologies, including viral vectors and non-viral delivery systems, enabling effective modulation of gene expression. With increased investments in R&D, Gene Therapy is witnessing a transformative phase, allowing for improved safety and efficacy. On the other hand, RNA Interference, recognized as an emerging application, focuses on silencing specific genes to inhibit disease progression. Its potential lies in addressing conditions that currently lack effective treatments. The continuous evolution in synthetic RNA design and delivery mechanisms positions RNA Interference as a crucial player, capable of complementing Gene Therapy and paving the way for future advancements.

### By Type: DNA Based Therapeutics (Largest) vs. RNA Based Therapeutics (Fastest-Growing)

In the US Nucleic Acid Based Therapeutics Market, DNA-based therapeutics currently hold the largest market share, thanks to their established applications in various genetic disorders and their robustness in targeting specific cellular pathways. On the other hand, RNA-based therapeutics are quickly gaining traction, capturing attention with their innovative approaches in gene silencing and mRNA vaccine technologies, which have been especially relevant in recent public health events. This dynamic has created a competitive landscape where both therapeutic types coexist, appealing to different medical needs and patient demographics. The growth trends reveal a clear shift towards RNA-based therapeutics, driven by advancements in delivery mechanisms and an increasing number of clinical trials highlighting their efficacy and safety. This sector is also seeing a surge in investment and interest from biotech firms, prompting rapid developments in therapies aimed at oncology and rare diseases. Comparatively, while DNA-based therapies remain dominant, they are also exploring combination therapies to enhance their effectiveness further, illustrating a collaborative growth environment within the market.

Therapeutics: DNA Based (Dominant) vs. Oligonucleotide (Emerging)

DNA-based therapeutics are well-established, with a focus on gene replacement and therapy for genetically inherited diseases, leveraging the intrinsic properties of DNA to provide long-lasting effects. Their dominance is attributed to a strong investment in research and the presence of successful commercial therapies. In contrast, oligonucleotide therapeutics are emerging as a novel class, utilizing synthetic strands of nucleic acids to regulate gene expression and develop tailored treatments for various conditions. They are characterized by their ability to precisely target and modulate specific gene functions, positioning themselves as critical components in the future landscape of personalized medicine. As the industry evolves, oligonucleotides are expected to gain a larger foothold, driven by technological advancements and a growing regulatory acceptance.

### By End Use: Pharmaceutical Companies (Largest) vs. Research Institutions (Fastest-Growing)

In the US Nucleic Acid Based Therapeutics Market, the market share is predominantly held by pharmaceutical companies, which leverage their extensive resources and established infrastructures to develop and commercialize nucleic acid therapies. This segment benefits from significant investments in R&D and has built strong relationships with regulatory bodies, allowing for accelerated product development cycles. Meanwhile, research institutions, while smaller in overall market share, are rapidly growing due to their innovative approaches and collaborations with biotech firms that enhance their capabilities in therapeutic research.

Pharmaceutical Companies: Dominant vs. Research Institutions: Emerging

Pharmaceutical companies are seen as the dominant players in the US Nucleic Acid Based Therapeutics Market, harnessing their robust financial resources and established channels to lead in both research and commercial applications. Their significant investments in drug development allow them to advance novel nucleic acid therapeutics effectively. Conversely, research institutions are emerging as critical contributors to this market, driven by their agility and innovation. With the potential for groundbreaking discoveries, these institutions often collaborate with biotech firms and pharmaceutical companies, enhancing their research capabilities while positioning themselves as increasingly vital entities in advancing nucleic acid therapies.

## Regional Market Share Analysis

The US nucleic acid therapeutics market area will grow at a significant rate because new nucleic acid treatments are becoming more and more approved, and because nucleic acid extraction technology is readily available. The nation's market growth has reached its pinnacle and is anticipated to stay there for the duration of the projection period due to the availability of all positive elements. Additionally, the need for nucleic acid-based therapeutics is rising due to the increasing frequency of autoimmune illnesses in the population, which could boost the market's growth.

For example, in June 2022 the Autoimmune Association reported that over 31 million Americans suffer from autoimmune disorders, which are classified as 80–150 distinct chronic conditions. This demonstrates how common autoimmune diseases are in the intended audience.

## Competitive Benchmarking

The Nucleic Acid Based Therapeutics Market is currently characterized by a dynamic competitive landscape, driven by rapid advancements in genetic research and increasing demand for personalized medicine. Key players such as Amgen Inc (US), Gilead Sciences Inc (US), and Alnylam Pharmaceuticals Inc (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Amgen Inc (US) focuses on innovation through its robust pipeline of RNA-based therapies, while Gilead Sciences Inc (US) emphasizes strategic partnerships to bolster its research capabilities. Alnylam Pharmaceuticals Inc (US) is leveraging its expertise in RNA interference technology to expand its therapeutic offerings, collectively shaping a competitive environment that prioritizes innovation and collaboration.
In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies is significant, as they drive technological advancements and set industry standards, thereby shaping the overall market dynamics.
In December 2025, Gilead Sciences Inc (US) announced a strategic partnership with a leading biotechnology firm to co-develop a novel mRNA vaccine platform aimed at treating infectious diseases. This collaboration is expected to enhance Gilead's capabilities in the rapidly evolving vaccine landscape, positioning the company as a key player in the intersection of nucleic acid therapeutics and infectious disease management. The strategic importance of this partnership lies in its potential to accelerate the development of innovative therapies, thereby expanding Gilead's therapeutic portfolio.
In November 2025, Alnylam Pharmaceuticals Inc (US) received FDA approval for its latest RNAi therapeutic targeting a rare genetic disorder. This approval not only validates Alnylam's innovative approach but also reinforces its leadership in the RNA interference space. The strategic significance of this event is profound, as it opens new avenues for treatment options and enhances the company's reputation as a pioneer in nucleic acid-based therapies.
In October 2025, Amgen Inc (US) launched a new initiative aimed at integrating artificial intelligence (AI) into its drug discovery processes. This move is indicative of a broader trend within the industry, where companies are increasingly adopting digital technologies to streamline operations and enhance research outcomes. The strategic importance of this initiative lies in its potential to significantly reduce the time and cost associated with drug development, thereby providing Amgen with a competitive edge in the market.
As of January 2026, current trends in the Nucleic Acid Based Therapeutics Market are heavily influenced by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming increasingly vital, as companies recognize the need for collaboration to navigate the complexities of modern therapeutics. Looking ahead, competitive differentiation is likely to evolve, shifting from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition underscores the importance of agility and adaptability in a rapidly changing market.

## Report Scope

| MARKET SIZE 2024 | 131.19(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 136.6(USD Million) |
| MARKET SIZE 2035 | 196.45(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.74% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Amgen Inc (US), Gilead Sciences Inc (US), Regeneron Pharmaceuticals Inc (US), Vertex Pharmaceuticals Inc (US), Ionis Pharmaceuticals Inc (US), Sarepta Therapeutics Inc (US), Alnylam Pharmaceuticals Inc (US), Novartis AG (US) |
| Segments Covered | Application, Type, End Use |
| Key Market Opportunities | Advancements in gene editing technologies enhance therapeutic potential in the US Nucleic Acid Based Therapeutics Market. |
| Key Market Dynamics | Regulatory advancements and technological innovations drive growth in the US Nucleic Acid Based Therapeutics Market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US Nucleic Acid Based Therapeutics Market?**
A: The market valuation was 131.19 USD Million in 2024.

**Q: What is the projected market valuation for the US Nucleic Acid Based Therapeutics Market in 2035?**
A: The projected valuation for 2035 is 196.45 USD Million.

**Q: What is the expected CAGR for the US Nucleic Acid Based Therapeutics Market during the forecast period 2025 - 2035?**
A: The expected CAGR during this period is 3.74%.

**Q: Which companies are considered key players in the US Nucleic Acid Based Therapeutics Market?**
A: Key players include Amgen Inc, Gilead Sciences Inc, Regeneron Pharmaceuticals Inc, and others.

**Q: What are the main applications of nucleic acid-based therapeutics in the US market?**
A: Main applications include Gene Therapy, RNA Interference, Antisense Oligonucleotides, CRISPR Technology, and Vaccines.

**Q: What is the valuation range for Gene Therapy in the US Nucleic Acid Based Therapeutics Market?**
A: The valuation range for Gene Therapy is between 40.0 and 60.0 USD Million.

**Q: How do DNA Based Therapeutics compare to RNA Based Therapeutics in terms of market valuation?**
A: DNA Based Therapeutics have a valuation range of 30.0 to 45.0 USD Million, while RNA Based Therapeutics range from 40.0 to 60.0 USD Million.

**Q: What is the market valuation for pharmaceutical companies involved in nucleic acid-based therapeutics?**
A: Pharmaceutical companies have a valuation range of 50.0 to 75.0 USD Million.

**Q: What role do research institutions play in the US Nucleic Acid Based Therapeutics Market?**
A: Research institutions account for a valuation range of 30.0 to 45.0 USD Million.

**Q: What is the projected growth trend for oligonucleotide therapeutics in the US market?**
A: Oligonucleotide Therapeutics are projected to have a valuation range of 35.0 to 50.0 USD Million.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-nucleic-acid-therapeutics-market-12646*